Lymphoma is the most common hematologic cancer in dogs. The current standard of care is a doxorubicin-based combination chemotherapy protocol like CHOP, which provides the longest period of disease control and survival of approximately 12-13 months. Single agent protocols provide shorter remission periods of 1-7 months and are lower cost options for some owners. The article reviews various chemotherapy protocols ranging from prednisone to CHOP to help clinicians determine the best treatment plan for each patient and owner situation.
This document discusses the development and clinical trials of the drug bortezomib for the treatment of multiple myeloma. It summarizes that:
1) Bortezomib is a proteasome inhibitor that showed promise in preclinical studies for inhibiting multiple myeloma cell growth and inducing apoptosis.
2) Phase 1, 2 and 3 clinical trials demonstrated that bortezomib had significant anti-tumor activity and increased response rates, time to progression, and survival outcomes compared to other treatments in patients with relapsed or refractory multiple myeloma.
3) Combination trials using bortezomib with other drugs, such as dexamethasone, produced even higher response rates, suggesting
This document summarizes chemotherapy and antibiotic resistance. It discusses:
- The development of chemotherapy from the 1850s onward, including the discovery of sulfa drugs, penicillin, and streptomycin.
- How chemotherapeutic agents work, including their therapeutic index and mechanisms of action. Common classes of antimicrobial drugs like sulfa drugs, penicillin, and cephalosporins are described.
- How bacteria develop resistance to antibiotics through mechanisms like preventing drug entry, pumping drugs out, and enzymatically inactivating drugs. Genetic mutations also allow bacteria to evade antibiotics.
A good review of common GYN/ONC chemotherapy agents, especially for residents. Given at Wake Forest. Thanks to Dr. Michael Kelly for contributing and reviewing.
The document discusses principles of chemotherapy, including common agents and their mechanisms of action, side effects, and clinical considerations. It covers conventional chemotherapy drugs like alkylating agents, antimetabolites, and antitumor antibiotics, as well as their uses in treating cancers and managing side effects. The goal of chemotherapy is to cure cancer through eliminating all cancer cells, achieving long-term disease control, or palliating cancer symptoms.
- Chemotherapy began during WWII after observing bone marrow aplasia and lymphoid tissue dissolution in soldiers exposed to nitrogen mustard.
- Chemotherapy can be used definitively, as neoadjuvant therapy before surgery/radiation, adjuvantly after other treatments, or concurrently with radiation therapy.
- Common drugs include alkylating agents, antimetabolites, platinum compounds, taxanes, and antibiotics. They work by alkylating DNA, inhibiting DNA/RNA synthesis, or interfering with microtubule formation.
- Major toxicities include bone marrow suppression, gastrointestinal issues like mucositis, alopecia, and increased risk of infection. Careful patient monitoring is important during chemotherapy treatment.
Clinical pharmacology of drugs used in leishmaniasisDrSatyabrataSahoo
Leishmaniasis remains a public health problem, caused by protozoan parasites of the genus Leishmania transmitted by sandflies. It is estimated that 500,000 cases of visceral leishmaniasis occur annually, with over 500 million people at risk. Current treatments include pentavalent antimonials, amphotericin B, miltefosine, and paromomycin. However, drugs are becoming less effective as parasites develop resistance. Newer treatment options are needed to combat drug resistance and reduce toxicity.
the presentation include the different type of mechanism used by cancer cells to protect them from anticancer agents lead to produce resistance. the slide include definition of cancer as per WHO, type of tumors, treatment of cancer, goal of treatment, problem associated with chemotherapeutic agents, need of studing mechanisms of resistance for anticancer agents, resistance, different mechanism of drug resistance, epigenetics, drug efflux, drug inactivation, DNA damage repair, drug target alteration and cell death inhibitiond
This document provides an overview of novel drug delivery systems for herbal drugs. It discusses 8 types of novel herbal formulations: phytosomes, nanoemulsions, ethosomes, nanoparticles, microspheres, carbon nanotubes, niosomes, and hydrogels. Each formulation is described in terms of its structure, advantages, disadvantages, and applications. Phytosomes, for example, enhance absorption of herbal extracts and have been used to deliver liver-protectant flavonoids. Nanoemulsions can be taken by enteric route and used for cosmetic preparations. Nanoparticles are used to improve bioavailability and target drug delivery.
This document discusses the development and clinical trials of the drug bortezomib for the treatment of multiple myeloma. It summarizes that:
1) Bortezomib is a proteasome inhibitor that showed promise in preclinical studies for inhibiting multiple myeloma cell growth and inducing apoptosis.
2) Phase 1, 2 and 3 clinical trials demonstrated that bortezomib had significant anti-tumor activity and increased response rates, time to progression, and survival outcomes compared to other treatments in patients with relapsed or refractory multiple myeloma.
3) Combination trials using bortezomib with other drugs, such as dexamethasone, produced even higher response rates, suggesting
This document summarizes chemotherapy and antibiotic resistance. It discusses:
- The development of chemotherapy from the 1850s onward, including the discovery of sulfa drugs, penicillin, and streptomycin.
- How chemotherapeutic agents work, including their therapeutic index and mechanisms of action. Common classes of antimicrobial drugs like sulfa drugs, penicillin, and cephalosporins are described.
- How bacteria develop resistance to antibiotics through mechanisms like preventing drug entry, pumping drugs out, and enzymatically inactivating drugs. Genetic mutations also allow bacteria to evade antibiotics.
A good review of common GYN/ONC chemotherapy agents, especially for residents. Given at Wake Forest. Thanks to Dr. Michael Kelly for contributing and reviewing.
The document discusses principles of chemotherapy, including common agents and their mechanisms of action, side effects, and clinical considerations. It covers conventional chemotherapy drugs like alkylating agents, antimetabolites, and antitumor antibiotics, as well as their uses in treating cancers and managing side effects. The goal of chemotherapy is to cure cancer through eliminating all cancer cells, achieving long-term disease control, or palliating cancer symptoms.
- Chemotherapy began during WWII after observing bone marrow aplasia and lymphoid tissue dissolution in soldiers exposed to nitrogen mustard.
- Chemotherapy can be used definitively, as neoadjuvant therapy before surgery/radiation, adjuvantly after other treatments, or concurrently with radiation therapy.
- Common drugs include alkylating agents, antimetabolites, platinum compounds, taxanes, and antibiotics. They work by alkylating DNA, inhibiting DNA/RNA synthesis, or interfering with microtubule formation.
- Major toxicities include bone marrow suppression, gastrointestinal issues like mucositis, alopecia, and increased risk of infection. Careful patient monitoring is important during chemotherapy treatment.
Clinical pharmacology of drugs used in leishmaniasisDrSatyabrataSahoo
Leishmaniasis remains a public health problem, caused by protozoan parasites of the genus Leishmania transmitted by sandflies. It is estimated that 500,000 cases of visceral leishmaniasis occur annually, with over 500 million people at risk. Current treatments include pentavalent antimonials, amphotericin B, miltefosine, and paromomycin. However, drugs are becoming less effective as parasites develop resistance. Newer treatment options are needed to combat drug resistance and reduce toxicity.
the presentation include the different type of mechanism used by cancer cells to protect them from anticancer agents lead to produce resistance. the slide include definition of cancer as per WHO, type of tumors, treatment of cancer, goal of treatment, problem associated with chemotherapeutic agents, need of studing mechanisms of resistance for anticancer agents, resistance, different mechanism of drug resistance, epigenetics, drug efflux, drug inactivation, DNA damage repair, drug target alteration and cell death inhibitiond
This document provides an overview of novel drug delivery systems for herbal drugs. It discusses 8 types of novel herbal formulations: phytosomes, nanoemulsions, ethosomes, nanoparticles, microspheres, carbon nanotubes, niosomes, and hydrogels. Each formulation is described in terms of its structure, advantages, disadvantages, and applications. Phytosomes, for example, enhance absorption of herbal extracts and have been used to deliver liver-protectant flavonoids. Nanoemulsions can be taken by enteric route and used for cosmetic preparations. Nanoparticles are used to improve bioavailability and target drug delivery.
Chemotherapy works by destroying the RNA or DNA of rapidly replicating tumor cells, preventing them from continuing to divide. It is a systemic therapy, meaning the drugs travel throughout the body. There are several types of chemotherapy drugs that work in different ways, such as alkylating agents which directly damage DNA, antimetabolites which interfere with DNA and RNA growth, and anti-tumor antibiotics which alter DNA to stop cancer cell growth and multiplication. Chemotherapy can be administered orally, intravenously, via injection, or directly into body cavities, and is often given through multiple treatments to continue reducing the number of cancer cells.
Chemotherapeutic agents pharmacology /certified fixed orthodontic courses by...Indian dental academy
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.
Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
0091-9248678078
Biologics in psoriaisis – monitoring guidelines and special scenariosSandeep Lal V
1. Biologics are recombinant proteins or monoclonal antibodies that target specific proteins involved in psoriasis like TNF and IL-17.
2. Guidelines recommend biologics be initiated and monitored by specialists experienced in psoriasis and to consider both psoriasis and psoriatic arthritis if a patient has both.
3. Special considerations are required when using biologics in patients with hepatitis B, hepatitis C, or HIV due to risks of viral reactivation or worsening that require monitoring and physician collaboration.
With newer biologics enriching the armentarium of Dermatologists almost everyday,it is often difficult to recollect all the information at a time.This powerpoint helps to summarise the pathogenesis of psoriasis as well asdifferent aspects of use of biologics in a nutshell.
1. The document discusses the major events in the development of modern chemotherapy and control of tuberculosis from 1940-1977, including key clinical trials of various drug regimens.
2. Early trials in the 1940s-1950s established the effectiveness of streptomycin and combinations of streptomycin and para-aminosalicylic acid, but also found high rates of resistance with streptomycin alone.
3. Later trials from the 1950s-1970s explored regimens including isoniazid alone and in combination with other drugs, and found shorter-course regimens including rifampin and pyrazinamide were highly effective at sterilizing the bacteria.
Photodynamic therapy is effective & promising method forShahid Ansari
Photodynamic therapy uses photosensitizing drugs activated by light to kill cancer cells. It is an effective and promising method for cancer treatment. PDT involves injecting a photosensitizer which is absorbed by cancer cells and activated by light, producing reactive oxygen that destroys the cancer cells. It has advantages over other therapies like fewer side effects and the ability to precisely target tumors with minimal damage to healthy tissue. Limitations include light not penetrating deeply into the body and it being mostly used for superficial tumors.
This presentation focuses on appropriate selection of antibiotics in the ICU and discusses different strategies to optimize this selection with the aim to decrease resistance and improve appropriateness.
Chemotherapy uses antineoplastic drugs to destroy tumor cells by interfering with cell function and reproduction. The goal is to kill as many tumor cells as possible while minimizing harm to healthy cells. Chemotherapy is used in different settings such as adjuvant therapy after tumor removal to prevent recurrence, neoadjuvant therapy before surgery to shrink tumors, and for palliation of metastatic disease. Higher drug doses over shorter periods may be more effective due to acquired resistance in tumor cells. Chemotherapy is administered via several routes including oral, intravenous, intramuscular, and intrathecal routes.
Pharmacokinetics And Pharmacodynamic of Biotechnology Drugs - Trilok ShahareTrilok Shahare
This document discusses the pharmacokinetics and pharmacodynamics of biotechnology drugs. It begins by defining pharmacokinetics as the study of what the body does to a drug and pharmacodynamics as the study of a drug's biochemical and physiological effects. The document then examines various types of biotechnology products including proteins and peptides, monoclonal antibodies, oligonucleotides, vaccines, and gene therapies. It provides examples and applications of each type of biotechnology drug.
Presentation on chemotherapy and medicines.IndranilBhuyan
This document presents information on chemotherapy and medicines. It discusses the objectives of chemotherapy which include maximizing cancer cell death, curing cancer patients, controlling tumor growth, and extending life. The history of chemotherapy is outlined beginning with Paul Ehrlich in the early 1900s. The different types of chemotherapy like primary, adjuvant, neoadjuvant and concurrent are defined. The document also covers chemotherapy treatment process, advantages and disadvantages, and future perspectives like less toxic drugs and combination therapies. In conclusion, chemotherapy has advanced cancer treatment significantly though progress remains slow with continued understanding of cancer at a molecular level.
Design and optimizing of dosage regimen - pharmacology Areej Abu Hanieh
Drug therapy is initiated using a dosage regimen administered continuously or intermittently to achieve steady state concentrations. The regimen depends on factors like how rapidly steady state is needed. Steady state occurs when the rate of drug administration equals elimination, maintaining constant plasma levels. The goal is to refine regimens to provide maximum benefit with minimum adverse effects.
This document discusses chemotherapy for cancer treatment. It describes the main types of anticancer drugs as cytotoxic, targeted, and hormonal drugs. Cytotoxic drugs are further broken down into categories like alkylating agents, platinum coordination compounds, antimetabolites, and microtubule damaging agents. The document also covers general principles of chemotherapy like using combination therapy to achieve total tumour cell kill and targeting actively dividing cancer cells. Adverse effects of cytotoxic drugs are explained, like bone marrow depression and immunosuppression. The goal of cancer therapy is outlined as cure, prolonging remission, or palliation depending on the cancer type and stage.
1) Three studies showed lower mortality for patients with bacteremic pneumococcal pneumonia treated with antibiotic combination therapy compared to monotherapy.
2) Combination therapy including a beta-lactam plus macrolide is recommended for critically ill patients and those with bacteremic pneumococcal pneumonia based on evidence showing lower mortality compared to fluoroquinolone combinations or monotherapy.
3) The optimal duration of combination therapy for bacteremic pneumococcal pneumonia is unclear but guidelines recommend limiting it to 3-5 days once the pathogen is identified.
Tumour Hypoxia - detection and prognostic significanceMAASTRO clinic
Lecture by Dr. Heidi Lyng in the context of the Course: "Tumour Hypoxia: From Biology to Therapy III".
For the complete e-Course see http://www.myhaikuclass.com/MaastroClinic/metoxia
Drug resistant tuberculosis is defined as resistance of Mycobacterium tuberculosis to antitubercular drugs. It can be multidrug resistant (MDR), extensively drug resistant (XDR), or have other resistance patterns. Diagnosis involves culture and drug susceptibility testing using solid or liquid media, as well as molecular tests like CBNAAT and line probe assays. Treatment requires specialized regimens using second line drugs for longer periods. Patient follow up assesses treatment response through repeated sputum cultures. Newer drugs like bedaquiline and delamanid are being added to treatment regimens to improve outcomes for drug resistant tuberculosis.
Antibody drug conjugates current status and future perspectivesPranav Sopory
ADC are an emerging class of new anti-cancer agents.
They are the future of oncological management.
Discussed here are their past, present and probable future.
This document provides information about cancer and chemotherapy. It defines cancer as uncontrolled cell growth that can invade healthy tissue. Chemotherapy uses drugs to destroy cancer cells and works by stopping or slowing cancer cell growth and division. Common side effects occur due to chemotherapy's effects on healthy cells that also rapidly divide. The document outlines cancer types, symptoms, diagnosis, staging, treatment modalities including chemotherapy, chemotherapy mechanisms and classifications of cytotoxic drugs, routes of administration, side effects, and nursing considerations for chemotherapy administration and management of side effects.
This document discusses multidrug-resistant tuberculosis (MDR-TB), which kills over 5,000 people per day globally and is a major public health crisis. MDR-TB is highly prevalent in many developing countries and is increasingly difficult to treat due to genetic mutations that make the tuberculosis bacteria resistant to multiple drugs. Proper treatment requires identifying the right combination of at least 4-6 effective drugs through culture and sensitivity testing, directly observing patients to ensure proper adherence, and treating for a minimum of 18-24 months. However, MDR-TB treatment faces many challenges including limited diagnostic capacity, improper prescribing practices, and socioeconomic factors affecting patient compliance.
Chemotherapy is the main treatment for disseminated cancers. It involves using multiple drugs in cycles to target rapidly dividing cancer cells. Common drugs include alkylating agents, antimetabolites, microtubule inhibitors, and monoclonal antibodies. Combination chemotherapy aims to maximize responses while avoiding overlapping toxicities. Doses are based on body surface area and adjusted for individual factors. Treatment intervals allow time for normal tissues to recover between cycles. Toxicities include myelosuppression, nausea/vomiting, and alopecia. Response is evaluated based on tumor shrinkage or progression.
This document summarizes information on chronic urticaria, including its prevalence, causes, impact on quality of life, and treatment options. It notes that chronic urticaria affects approximately 1% of people with acute urticaria and has a significant negative impact on quality of life. First-line treatment includes non-sedating antihistamines, sometimes at higher off-label doses. If patients do not respond sufficiently to antihistamines alone, second-line options include doxepin, leukotriene antagonists, short-term corticosteroids, dapsone, sulfasalazine, and narrowband UVB phototherapy. The document reviews evidence on the efficacy and safety of these second-
Chemotherapy works by destroying the RNA or DNA of rapidly replicating tumor cells, preventing them from continuing to divide. It is a systemic therapy, meaning the drugs travel throughout the body. There are several types of chemotherapy drugs that work in different ways, such as alkylating agents which directly damage DNA, antimetabolites which interfere with DNA and RNA growth, and anti-tumor antibiotics which alter DNA to stop cancer cell growth and multiplication. Chemotherapy can be administered orally, intravenously, via injection, or directly into body cavities, and is often given through multiple treatments to continue reducing the number of cancer cells.
Chemotherapeutic agents pharmacology /certified fixed orthodontic courses by...Indian dental academy
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.
Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
0091-9248678078
Biologics in psoriaisis – monitoring guidelines and special scenariosSandeep Lal V
1. Biologics are recombinant proteins or monoclonal antibodies that target specific proteins involved in psoriasis like TNF and IL-17.
2. Guidelines recommend biologics be initiated and monitored by specialists experienced in psoriasis and to consider both psoriasis and psoriatic arthritis if a patient has both.
3. Special considerations are required when using biologics in patients with hepatitis B, hepatitis C, or HIV due to risks of viral reactivation or worsening that require monitoring and physician collaboration.
With newer biologics enriching the armentarium of Dermatologists almost everyday,it is often difficult to recollect all the information at a time.This powerpoint helps to summarise the pathogenesis of psoriasis as well asdifferent aspects of use of biologics in a nutshell.
1. The document discusses the major events in the development of modern chemotherapy and control of tuberculosis from 1940-1977, including key clinical trials of various drug regimens.
2. Early trials in the 1940s-1950s established the effectiveness of streptomycin and combinations of streptomycin and para-aminosalicylic acid, but also found high rates of resistance with streptomycin alone.
3. Later trials from the 1950s-1970s explored regimens including isoniazid alone and in combination with other drugs, and found shorter-course regimens including rifampin and pyrazinamide were highly effective at sterilizing the bacteria.
Photodynamic therapy is effective & promising method forShahid Ansari
Photodynamic therapy uses photosensitizing drugs activated by light to kill cancer cells. It is an effective and promising method for cancer treatment. PDT involves injecting a photosensitizer which is absorbed by cancer cells and activated by light, producing reactive oxygen that destroys the cancer cells. It has advantages over other therapies like fewer side effects and the ability to precisely target tumors with minimal damage to healthy tissue. Limitations include light not penetrating deeply into the body and it being mostly used for superficial tumors.
This presentation focuses on appropriate selection of antibiotics in the ICU and discusses different strategies to optimize this selection with the aim to decrease resistance and improve appropriateness.
Chemotherapy uses antineoplastic drugs to destroy tumor cells by interfering with cell function and reproduction. The goal is to kill as many tumor cells as possible while minimizing harm to healthy cells. Chemotherapy is used in different settings such as adjuvant therapy after tumor removal to prevent recurrence, neoadjuvant therapy before surgery to shrink tumors, and for palliation of metastatic disease. Higher drug doses over shorter periods may be more effective due to acquired resistance in tumor cells. Chemotherapy is administered via several routes including oral, intravenous, intramuscular, and intrathecal routes.
Pharmacokinetics And Pharmacodynamic of Biotechnology Drugs - Trilok ShahareTrilok Shahare
This document discusses the pharmacokinetics and pharmacodynamics of biotechnology drugs. It begins by defining pharmacokinetics as the study of what the body does to a drug and pharmacodynamics as the study of a drug's biochemical and physiological effects. The document then examines various types of biotechnology products including proteins and peptides, monoclonal antibodies, oligonucleotides, vaccines, and gene therapies. It provides examples and applications of each type of biotechnology drug.
Presentation on chemotherapy and medicines.IndranilBhuyan
This document presents information on chemotherapy and medicines. It discusses the objectives of chemotherapy which include maximizing cancer cell death, curing cancer patients, controlling tumor growth, and extending life. The history of chemotherapy is outlined beginning with Paul Ehrlich in the early 1900s. The different types of chemotherapy like primary, adjuvant, neoadjuvant and concurrent are defined. The document also covers chemotherapy treatment process, advantages and disadvantages, and future perspectives like less toxic drugs and combination therapies. In conclusion, chemotherapy has advanced cancer treatment significantly though progress remains slow with continued understanding of cancer at a molecular level.
Design and optimizing of dosage regimen - pharmacology Areej Abu Hanieh
Drug therapy is initiated using a dosage regimen administered continuously or intermittently to achieve steady state concentrations. The regimen depends on factors like how rapidly steady state is needed. Steady state occurs when the rate of drug administration equals elimination, maintaining constant plasma levels. The goal is to refine regimens to provide maximum benefit with minimum adverse effects.
This document discusses chemotherapy for cancer treatment. It describes the main types of anticancer drugs as cytotoxic, targeted, and hormonal drugs. Cytotoxic drugs are further broken down into categories like alkylating agents, platinum coordination compounds, antimetabolites, and microtubule damaging agents. The document also covers general principles of chemotherapy like using combination therapy to achieve total tumour cell kill and targeting actively dividing cancer cells. Adverse effects of cytotoxic drugs are explained, like bone marrow depression and immunosuppression. The goal of cancer therapy is outlined as cure, prolonging remission, or palliation depending on the cancer type and stage.
1) Three studies showed lower mortality for patients with bacteremic pneumococcal pneumonia treated with antibiotic combination therapy compared to monotherapy.
2) Combination therapy including a beta-lactam plus macrolide is recommended for critically ill patients and those with bacteremic pneumococcal pneumonia based on evidence showing lower mortality compared to fluoroquinolone combinations or monotherapy.
3) The optimal duration of combination therapy for bacteremic pneumococcal pneumonia is unclear but guidelines recommend limiting it to 3-5 days once the pathogen is identified.
Tumour Hypoxia - detection and prognostic significanceMAASTRO clinic
Lecture by Dr. Heidi Lyng in the context of the Course: "Tumour Hypoxia: From Biology to Therapy III".
For the complete e-Course see http://www.myhaikuclass.com/MaastroClinic/metoxia
Drug resistant tuberculosis is defined as resistance of Mycobacterium tuberculosis to antitubercular drugs. It can be multidrug resistant (MDR), extensively drug resistant (XDR), or have other resistance patterns. Diagnosis involves culture and drug susceptibility testing using solid or liquid media, as well as molecular tests like CBNAAT and line probe assays. Treatment requires specialized regimens using second line drugs for longer periods. Patient follow up assesses treatment response through repeated sputum cultures. Newer drugs like bedaquiline and delamanid are being added to treatment regimens to improve outcomes for drug resistant tuberculosis.
Antibody drug conjugates current status and future perspectivesPranav Sopory
ADC are an emerging class of new anti-cancer agents.
They are the future of oncological management.
Discussed here are their past, present and probable future.
This document provides information about cancer and chemotherapy. It defines cancer as uncontrolled cell growth that can invade healthy tissue. Chemotherapy uses drugs to destroy cancer cells and works by stopping or slowing cancer cell growth and division. Common side effects occur due to chemotherapy's effects on healthy cells that also rapidly divide. The document outlines cancer types, symptoms, diagnosis, staging, treatment modalities including chemotherapy, chemotherapy mechanisms and classifications of cytotoxic drugs, routes of administration, side effects, and nursing considerations for chemotherapy administration and management of side effects.
This document discusses multidrug-resistant tuberculosis (MDR-TB), which kills over 5,000 people per day globally and is a major public health crisis. MDR-TB is highly prevalent in many developing countries and is increasingly difficult to treat due to genetic mutations that make the tuberculosis bacteria resistant to multiple drugs. Proper treatment requires identifying the right combination of at least 4-6 effective drugs through culture and sensitivity testing, directly observing patients to ensure proper adherence, and treating for a minimum of 18-24 months. However, MDR-TB treatment faces many challenges including limited diagnostic capacity, improper prescribing practices, and socioeconomic factors affecting patient compliance.
Chemotherapy is the main treatment for disseminated cancers. It involves using multiple drugs in cycles to target rapidly dividing cancer cells. Common drugs include alkylating agents, antimetabolites, microtubule inhibitors, and monoclonal antibodies. Combination chemotherapy aims to maximize responses while avoiding overlapping toxicities. Doses are based on body surface area and adjusted for individual factors. Treatment intervals allow time for normal tissues to recover between cycles. Toxicities include myelosuppression, nausea/vomiting, and alopecia. Response is evaluated based on tumor shrinkage or progression.
This document summarizes information on chronic urticaria, including its prevalence, causes, impact on quality of life, and treatment options. It notes that chronic urticaria affects approximately 1% of people with acute urticaria and has a significant negative impact on quality of life. First-line treatment includes non-sedating antihistamines, sometimes at higher off-label doses. If patients do not respond sufficiently to antihistamines alone, second-line options include doxepin, leukotriene antagonists, short-term corticosteroids, dapsone, sulfasalazine, and narrowband UVB phototherapy. The document reviews evidence on the efficacy and safety of these second-
ANTI TUBERCULAR DRUGS AND THEIR ACTIONS.VishnuK746257
This document discusses the anti tubercular drugs. It provides information about the classification[first line (isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin) and second line drugs(ethionamide,prothionamide, cycloserine, para amino salicylic acid and fluoroquinolones)], mechanism of action, pharmacokinetics, adverse effects, dose and brand names of antitubercular drugs.
Tuberculosis incidence in india and world
This document discusses various modalities for treating cancer including chemotherapy. It provides details on the mechanisms of action, goals and classifications of different chemotherapeutic agents. It describes how certain drugs like methotrexate, cyclophosphamide and cisplatin directly damage DNA to inhibit cell proliferation. It also discusses concepts like drug resistance, cell cycle specificity and overcoming resistance through combination therapy. The document concludes by summarizing adverse effects of major drug classes and approaches to manage toxicities.
This document provides an overview of novel drug delivery systems (NDDS). It discusses the need for NDDS due to disadvantages of current drug therapies, such as degradation in the gastrointestinal tract and first-pass metabolism. The document outlines various types of NDDS, including controlled drug delivery systems, targeted drug delivery systems, and site-specific delivery systems. It also discusses different routes of administration and various polymer carriers that can be used to develop NDDS, such as liposomes, nanoparticles, and microspheres. The overall summary is that NDDS aim to increase drug stability, control release rates, and target drug delivery for improved patient outcomes and compliance.
This document describes the development of a novel intratumoral drug delivery system using interstitial chemotherapy devices. The system aims to deliver chemotherapy drugs directly into solid tumors via implantable polymeric devices to achieve higher drug concentrations and more homogeneous distribution compared to systemic chemotherapy. The document outlines the design of biodegradable polymer implants loaded with cisplatin as a model drug. In vitro studies show sustained release of cisplatin from the implants over 1 month in a rate dependent on drug loading. The system has the potential for localized treatment with fewer systemic side effects.
Cyclosporine is an immunosuppressive drug that was originally isolated from fungi in 1970 and approved by the FDA for transplant rejection in 1983. It is a cyclic polypeptide consisting of 11 amino acids that acts by inhibiting T cell activation through the calcineurin/NFAT pathway. It has since been approved for treating various dermatological conditions like psoriasis, atopic dermatitis, and pyoderma gangrenosum. While effective, cyclosporine use can cause nephrotoxicity, hypertension, and increased risk of infection and skin cancer with long term use. It can also interact with various other drugs that are metabolized through the CYP3A4 pathway.
This document discusses antimycobacterial drugs used to treat tuberculosis and other mycobacterial infections. It provides information on various first-line drugs including isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. It notes that combinations of two or more drugs are required to treat mycobacterial infections due to slow growth and potential drug resistance. Treatment must be prolonged, typically for months to years, to eliminate both actively dividing and dormant bacteria. Second-line drugs are discussed for treatment of multi-drug resistant infections. Worldwide tuberculosis statistics and drug regimens are also summarized.
Treatment of chronic inflammatory demyelinating polyneuropathyMohamadAlhes
This document summarizes treatment options for chronic inflammatory demyelinating polyneuropathy (CIDP). The main treatments are immunoglobulin therapy (IVIG or SCIG), corticosteroids, and plasmapheresis. IVIG and plasmapheresis provide equivalent short-term benefits but most patients require ongoing intermittent treatment. Corticosteroids can induce remission but have significant side effects with long-term use. Treatment must be tailored to the individual patient based on disease severity and response to initial therapies.
This document discusses various methods of altered fractionation in radiation therapy. It begins with an introduction to the history of fractionation based on experiments in the 1920s-1930s. It then covers radiobiological principles of fractionation including repair of sublethal damage and reoxygenation. Various methods of altered fractionation are classified and described, including hyperfractionation, accelerated fractionation using different schedules, hypofractionation, and continuous hyperfractionated accelerated radiotherapy (CHART). Comparisons are made between conventional and altered fractionation schedules.
Norbert Sipos: Principles of cancer therapyKatalin Cseh
The document discusses principles of cancer therapy including chemotherapy and radiation therapy. It covers topics like evaluating malignancies, determining likelihood of response to treatment, cell cycle specifics of chemotherapy, and principles of combination chemotherapy. The document also provides details on treating specific cancers like vulvar cancer through surgery, radiation, and chemotherapy.
This document summarizes the different treatment regimens that have been used for leprosy over time. It begins with pre-antibiotic treatments using chaulmoogra oil. It then outlines the evolution of multidrug therapy (MDT) regimens recommended by WHO, from DDS monotherapy in the 1950s to various MDT combinations in the 1980s-1990s using drugs like rifampicin, ofloxacin, and minocycline. Newer experimental regimens tested included shorter durations of therapy, intermittent therapy, and single-dose therapies. Uniform MDT aiming to simplify treatment without classification was also studied.
This document summarizes treatment approaches for tuberculosis. It discusses that TB is caused by Mycobacterium tuberculosis and effective treatment requires a minimum of 6 months. The standard treatment involves a 2 month induction phase with at least isoniazid, rifampin and pyrazinamide followed by a 4 month continuation phase with isoniazid and rifampin. It notes areas of uncertainty around treatment duration and monitoring as well as challenges in identifying patients who may need prolonged treatment and improving regimens using pharmacokinetic data.
Basic Principles of Chemotherapy administration .pptxMona Quenawy
basic principles of chemotherapy including the treatment aim by definitions. Types and classes of chemotherapeutic agents and drug combination idea and its side effects .how to proceed prior to administration
This document provides an overview of Novel Drug Delivery Systems (NDDS). It defines NDDS as approaches that transport pharmaceutical compounds safely in the body as needed. The goals of NDDS are to provide therapeutic drug levels at the target site with minimal side effects, degradation, and increased bioavailability. Ideal NDDS would safely deliver drugs in a controlled and sustained manner over time at the site of action. The document discusses various NDDS approaches and terminologies and provides examples of controlled, sustained, delayed, and extended release systems.
Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient's drug therapy.
The success of drug therapy is highly dependent on the choice of the drug, the drug product, and the design of the dosage regimen. The choice of the drug is generally made by the physician after careful patient diagnosis and physical assessment.
This document discusses cancer chemotherapy and its goals, approaches, and challenges. It covers:
1. The goals of cancer treatment include being curative, palliative, or adjuvant. Major treatment modalities include surgery, radiotherapy, chemotherapy, and others.
2. Chemotherapy works by targeting the cell cycle and killing a constant fraction of cancer cells per dose. It is more effective against cancers with high growth fractions.
3. Challenges include drug resistance, toxic side effects that impact rapidly dividing normal cells, and managing those toxicities. Combination chemotherapy aims to overcome these challenges.
This document discusses cancer and chemotherapy drugs. It defines cancer as uncontrolled cell growth that can form tumors. Chemotherapy drugs are described as targeting and destroying cancer cells. Common types of chemotherapy drugs are discussed, including their mechanisms of action, examples, doses, and indications. Adverse effects are outlined as well as contraindications and drug interactions. Guiding principles of chemotherapy like total cell kill, early diagnosis/treatment, combination therapy, and intermittent regimens are presented. Nursing responsibilities in caring for patients undergoing chemotherapy are also summarized.
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...iosrphr_editor
This document discusses multidrug resistant tuberculosis (MDR-TB) and the DOTS-Plus treatment guidelines. It provides background on the emergence of MDR-TB and the need for DOTS-Plus programs to treat patients resistant to first-line drugs. DOTS-Plus utilizes second-line drugs that are more toxic and difficult to administer. The standard Category IV regimen and dosages are described. Close monitoring is needed to detect adverse drug reactions early. Managing MDR-TB in special groups like pregnant women and those with HIV presents additional challenges.
Similar to Lymphoma which chemotherapy protocol and why (20)
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
2. 158 Topics in Companion Animal Medicine
Table 1. Chemotherapy Protocols
Protocol Drug Dosage Follow-up
Single-agent prednisone 2 mg/kg/d ϫ 14 d, then 1.5 mg/kg/d ϫ 1- to 2-month median disease control
14 d, then 1 mg/kg/d ϫ 14 d, then 1 mg/kg
every other day indefinitely
Single agent doxorubicin2 30 mg/m2 IV every 21 days ϫ 5 treatments. ϳ7-month median disease control.
Dogs weighing Ͼ15 kg should be dosed at Median survival of 9 months.
1 mg/kg.
CCNU9 70 mg/m2 PO every 21 d ϫ 5 treatments ϳ3-month median survival, including
dogs treated with rescue therapies.
Prednisone 2 mg/kg/d ϫ 7 d, dose tapered over the Median duration of response: ϳ1 month
next 3 wk
COP (induction)16 6 weekly cycles of the following: Median survival not provided. Median
duration of response: ϳ3 months
Vincristine day 1: 0.7 mg/m2 IV
Cyclophosphamide days 4-7: 50 mg/m2 PO
Prednisone days 1-7: 20 mg/m2 PO every 12 h
COP (maintenance)16 Repeated weekly until relapse:
Methotrexate days 1 and 5: 5 mg/m2 PO
Cyclophosphamide day 3: 100 mg/m2 PO
Prednisone days 1, 3, 5, 7: 20 mg/m2 PO
Abbreviations: CCNU, cyclohexylchloroethylnitrosourea; COP, cyclophosphamide, Oncovin, and prednisone; IV, intravenously; PO, orally.
Disadvantages of this protocol include the potential for the veloped as a cardioprotective agent for individuals under-
common chemotherapy side effects of myelosuppression going doxorubicin therapy.6 With this goal, it may be admin-
and/or gastrointestinal upset, and the potential for the doxo- istered intravenously over 15 to 20 minutes immediately
rubicin-specific side effects of extravasation injury, anaphy- before doxorubicin. Another significant use of dexrazoxane
lactic reaction during or shortly after drug administration, is that, anecdotally, it completely abrogates doxorubicin-as-
and development of dilated cardiomyopathy and heart fail- sociated extravasation injury when administered within 3
ure. As mentioned previously, judicious administration of hours of extravasation.7,8 There is no set protocol for the use
antiemetics may circumvent nausea or vomiting, and use of a of dexrazoxane after doxorubicin extravasation. A conserva-
carefully placed intravenous catheter minimizes the risk of tive recommendation is to administer it within 3 hours of
extravasation injury. As with most chemotherapy protocols, doxorubicin extravasation and repeat the dose at 24 and 48
a blood count is measured the day of therapy as well as 7 days hours. Dexrazoxane itself is a vesicant, so caution is neces-
after each treatment. Dogs with a neutrophil count Ͼ2000 sary when administering this drug.
cells/L or a platelet count Ͼ75,000 cells/L should not be Some clients may shy away from treating their pets with
treated, and, if the 7-day blood count demonstrates a neutro- intravenous medications but are open to orally administered
phil count Ͼ1000 cells/L, fluoroquinolone antibiotics chemotherapy drugs. Further, some dogs may be fractious or
should be instituted for a minimum of 5 days. If the patient is difficult to restrain for IV treatments and oral therapy may be
actually febrile in addition to being neutropenic on day 7, an option. Although orally administered, it is still important
intravenous fluoroquinolones and ampicillin should be initi- to be sure that blood counts are measured before and at
ated. Anaphylactoid reactions are rarely associated with the indicated intervals after chemotherapy administration.
first treatment, but dogs should be carefully assessed for er-
ythema, urticaria, facial swelling, or even flatulence or nau- Cyclohexylchloroethylnitrosourea (CCNU);
sea (drooling or actual vomiting) during the 30 minutes after
doxorubicin administration. Should any of these signs arise,
(Lomustine) and Prednisone
2 mg/kg of diphenhydramine intramuscularly and 0.2 mg/kg This combination has been investigated as a treatment for
dexamethasone sodium phosphate (SP), also administered lymphoma.9 CCNU is a potent alkylating agent that may
intramuscularly, typically resolve the problem, and any re- cause profound neutropenia, cumulatively it may cause po-
maining dose can be administered once the reaction subsides. tentially irreversible thrombocytopenia, and it is associated
Animals that have had a reaction to doxorubicin should be with potentially fatal hepatotoxicity.10,11 Questions regard-
premedicated with both diphenhydramine and dexametha- ing the efficacy of hepato-supportive/protective agents (eg,
sone SP to minimize the risk of a second reaction. Finally, SAMe or milk thistle) in preventing or resolving CCNU-
dexrazoxane is a free-radical scavenging agent that was de- induced liver damage are unanswered as of the writing of this
3. Volume 24, Number 3, August 2009 159
Table 2. University of Wisconsin–Madison CHOP protocol18
Week and Drug Dose Follow-up
1: Vincristine 0.7 mg/m2 IV 2 mg/kg/d Median survival: ϳ13 months
Prednisone Median disease control: ϳ9 months
2: Cyclophosphamide 250 mg/m2 IV or PO
Prednisone 1.5 mg/kg/d
3: Vincristine 0.7 mg/m2 IV
Prednisone 1 mg/kg/d
4: Doxorubicin 30 mg/m2 IV (if Յ 15 kg: 1 mg/kg)
Prednisone 0.5 mg/kg/d
5: No drugs
6: Vincristine 0.7 mg/m2 IV
7: Cyclophosphamide 250 mg/m2 IV or PO
8: Vincristine 0.7 mg/m2 IV
9: Doxorubicin 30 mg/m2 IV (if Յ 15 kg: 1 mg/kg)
11: Vincristine 0.7 mg/m2 IV
13: Cyclophosphamide 250 mg/m2 IV or PO
15: Vincristine 0.7 mg/m2 IV
17: Doxorubicin 30 mg/m2 IV (if Յ 15 kg: 1 mg/kg)
19: Vincristine 0.7 mg/m2 IV
21: Cyclophosphamide 250 mg/m2 IV or PO
23: Vincristine 0.7 mg/m2 IV
25: Doxorubicin 30 mg/m2 IV (if Յ 15 kg: 1 mg/kg)
Abbreviations: CHOP, cyclophosphamide, hydroxyl-daunorubicin (doxorubicin; Adriamycin), Oncovin (vincristine), and prednisone; IV, intrave-
nously; PO, orally.
article. Thus, although it is an effective anticancer agent, care for the treatment of canine lymphoma. There are many
patients undergoing CCNU therapy must be carefully moni- variations of this particular combination of drugs, and all
tored. Because of the relatively poor median duration of tu- have similar median disease-free intervals and overall sur-
mor control (40 days) and overall survival (110 days), and vival times.17-23 Because of similarities in disease control and
because of the potentially significant toxicities, this protocol overall survival, only one CHOP protocol has been outlined
is not recommended as first-line therapy for dogs with lym- in this chapter (Table 2).18 Variations from this protocol
phoma. It is the opinion of this author that CCNU (combined include differences in the order of drug administration, addi-
with L-asparaginase and prednisone) is best reserved as a tion of L-asparaginase or methotrexate to the protocol, slight
rescue option for dogs with relapsed lymphoma.12 differences in drug doses, and increased or decreased protocol
duration. A 19-week CHOP protocol has been reported.19 The
Cyclophosphamide, Oncovin, and Prednisone 19-week protocol is essentially an accelerated version of
the University of Wisconsin-Madison protocol outlined in
The combination of cyclophosphamide, Oncovin (vincris-
Table 2. Instead of going to every-other-week treatments for
tine) and prednisone is a time-honored and effective way to
the last 8 doses of chemotherapy, weekly treatment intervals
treat lymphoma.2-16 The advantages include relatively few
are maintained. The median duration of first remission for
drugs in the protocol and relatively low expense associated
the 30 dogs treated with the 19-week protocol was reported
with each treatment. Disadvantages include the potential
as 174 days, compared with a median of 282 days for 53 dogs
specific side effects of sterile hemorrhagic cystitis from cyclo-
treated with the 25-week protocol. Because a “head to head”
phosphamide and perivascular irritation from vincristine ex-
travasation (see CHOP section for more discussion). Other comparison between the 25-week and 19-week protocols has
disadvantages include the prolonged maintenance portion of not been published, it is impossible to directly compare the
the protocol and the fact that some articles report shorter two. The main advantage to the 19-week protocol is that it is
median periods of disease control and overall survival.2 over sooner, perhaps making it logistically easier for some
clients.
According to 2 studies, the seemingly significant omission
CHOP Protocols and Beyond of L-asparaginase actually makes no apparent difference in
As mentioned earlier in this article, most veterinary oncolo- protocol efficacy.16,24 Thus, L-asparaginase can be saved for
gists consider CHOP protocols (consisting of cyclophospha- use as a rescue drug. Methotrexate, an antimetabolite that
mide, hydroxyl-daunorubicin [doxorubicin; Adriamycin], inhibits dihydrofolate reductase and depletes the body of
Oncovin [vincristine], and prednisone) as the standard of folates, was once a staple of combination chemotherapy pro-